Hellenic Cooperative Oncology Group
58
4
5
31
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
12.1%
7 terminated/withdrawn out of 58 trials
81.6%
-4.9% vs industry average
3%
2 trials in Phase 3/4
0%
0 of 31 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (58)
Clinical Outcomes and Prognostic Biomarkers Exploration Between HER2 Low and HER2 Zero eBC Patients
Role: lead
The Prognostic Role of TILs and CD8+ T Cells in Operable Breast Cancer
Role: lead
PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer
Role: collaborator
Elements of Adaptive Immunity in Epithelial Ovarian Cancer
Role: lead
Pooled Analysis of Patients With Early-stage Breast Cancer Treated With Adjuvant Dose-dense Sequential Chemotherapy: a Hellenic Cooperative Oncology Group (HeCOG) Study.
Role: lead
Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan
Role: lead
Mechanisms of Response and Resistance to Innovative Treatments in Patients With Locally Advanced or Metastatic Breast Cancer
Role: lead
Gene Molecular Alterations as Disease Prognostic Markers in Patients With Non-small Cell Lung Cancer (NSCLC)
Role: lead
Real-world Data in Patients With Breast Cancer Treated With Abemaciclib
Role: lead
HNSCC Immuno-genomics Project
Role: lead
Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients
Role: collaborator
Real-world Data of Paclitaxel and Ramucirumab Compared to Other Treatment Regimens in Advanced Gastric Cancer
Role: lead
Cellular Immune Responses in Triple-negative Breast Cancer - High Throughput Immunogenetic Studies
Role: collaborator
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Role: collaborator
Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer
Role: lead
RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
Role: lead
Detection of Germline and Somatic Pathogenic Variants in Patients With de Novo Metastatic Breast Cancer
Role: lead
Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer
Role: lead
Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer
Role: lead
Investigation of Genomic Alteration in Patients With Luminal A or Luminal B Subtypes
Role: lead